Dr. Andrea Apolo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
The anti-PD-L1 antibody avelumab has shown promising results in refractory, metastatic urothelial carcinoma. The checkpoint inhibitor had clinical activity, showing tumor shrinkage, says Apollo. There is no data yet regarding overall survival, but durable responses have been observed. This development is exciting for bladder cancer research, Apolo adds.
Next steps in the research include studying the agent in large clinical trials. These studies include identifying biomarkers and investigating potential combination therapies, Apolo says.
